Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription 07.09.2026 1 Am J Clin Pathol 2 Am J Hematol 1 Ann Hematol 3 Blood 2 BMC Cancer 3 Bone Marrow Transplant 4 Eur J Haematol 1 Exp Hematol 5 Int J Hematol 5 Leukemia 1 N Engl J Med 1 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Pathol

1. LOVE J, Verma T, Palmer P, Naresh KN, et al
   BRAF V600E-mutated marginal zone lymphoma may exhibit features that partially overlap with hairy cell leukemia.
   Am J Clin Pathol. 2026;166:aqag099.
   PubMed         Abstract available
   
   

   
   Am J Hematol

2. MAURILLO L, Buccisano F, Palmieri R, Cipriani M, et al
   Use of Peripheral Blood to Measure Residual Disease by Flow Cytometry in Adult Acute Myeloid Leukemia: Final Report of the Prospective GIMEMA AML1310 Trial.
   Am J Hematol. 2026 Sep 1. doi: 10.1002/ajh.70490.
   PubMed        
   
   
3. BHATT M, Zanwar S, Kumar S, Rajkumar SV, et al
   Primary Plasma Cell Leukemia.
   Am J Hematol. 2026 Aug 31. doi: 10.1002/ajh.70487.
   PubMed         Abstract available
   
   

   
   Ann Hematol

4. CHEN B, Qian S
   Sequencing asymmetry: the case for caution before first-line pirtobrutinib in chronic lymphocytic leukemia.
   Ann Hematol. 2026;105:404.
   PubMed         Abstract available
   
   

   
   Blood

5. SHRAIM R, Shi G, Li Y, Xu J, et al
   Multimodal analysis of CD38 in T-cell Acute Lymphoblastic Leukemia Identifies Combinatorial Therapeutic Strategies.
   Blood. 2026 Sep 2:blood.2026034575. doi: 10.1182/blood.2026034575.
   PubMed         Abstract available
   
   
6. LI Y, He X, Zhang L, Dong H, et al
   Targeting PRMT9 overcomes venetoclax resistance in AML by modulating splicing and inhibiting translation.
   Blood. 2026;148:1328-1343.
   PubMed         Abstract available
   
   
7. LI X, Aguilar-Navarro AG, Nader M, Jahangiri S, et al
   IFN-gamma drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.
   Blood. 2026;148:1277-1291.
   PubMed         Abstract available
   
   

   
   BMC Cancer

8. CUI D, Cui X, Xu X, Zhang W, et al
   Retraction Note: Identification of TLN1 as a prognostic biomarker to effect cell proliferation and differentiation in acute myeloid leukemia.
   BMC Cancer. 2026;26:1046.
   PubMed        
   
   
9. LIU S, Liu S, Hu Y, Deng J, et al
   Long-term cardiovascular risk in survivors of hematologic malignancies: a meta-analysis.
   BMC Cancer. 2026;26:1042.
   PubMed         Abstract available
   
   

   
   Bone Marrow Transplant

10. NAGLER A, Swoboda R, Ferhat AT, Blaise D, et al
    Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.
    Bone Marrow Transplant. 2026 Sep 2. doi: 10.1038/s41409-026-03012.
    PubMed         Abstract available
    
    
11. NAGLER A, Esteve J, Galimard JE, Wu D, et al
    Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2026 Aug 31. doi: 10.1038/s41409-026-03022.
    PubMed        
    
    
12. GUILLERAULT L, Saultier P, Domenech C, Ducassou S, et al
    Pregnancy outcomes in women conceiving after hematopoietic stem cell transplantation versus conventional chemotherapy for childhood or adolescent acute leukemia.
    Bone Marrow Transplant. 2026 Aug 31. doi: 10.1038/s41409-026-03019.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

13. MARTINO EA, Caserta S, Vigna E, Cutrona G, et al
    To Treat or Not to Treat: Navigating Early-Stage CLL in the Era of Targeted Therapy.
    Eur J Haematol. 2026;117:750-766.
    PubMed         Abstract available
    
    
14. MILOJKOVIC D, Cross NCP, Desai K, Frewin K, et al
    Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.
    Eur J Haematol. 2026;117:1072-1080.
    PubMed         Abstract available
    
    
15. ORIQUAT G, Al-Hasnaawei S, Mousa HM, Malathi H, et al
    Extracellular Vesicle-Based Approaches in Acute Myeloid Leukemia: Therapeutic Potential and Translational Challenges.
    Eur J Haematol. 2026 Aug 31. doi: 10.1111/ejh.70308.
    PubMed         Abstract available
    
    
16. BRINK M, van der Spek AC, Doorduijn JK, de Heer K, et al
    Treatment Patterns, Outcomes and Survival Trends in T-Cell Prolymphocytic Leukemia: A Nationwide Population-Based Study in the Netherlands.
    Eur J Haematol. 2026 Sep 4. doi: 10.1111/ejh.70312.
    PubMed         Abstract available
    
    

    
    Exp Hematol

17. CALLERA AF, Ferreira CP, Rech DF, Rosa ES, et al
    Phenotypic Remodeling and Functional Impairment of Circulating Neutrophils Are Associated with Infection-Related Mortality in Acute Myeloid Leukemia.
    Exp Hematol. 2026 Aug 29:105872. doi: 10.1016/j.exphem.2026.105872.
    PubMed         Abstract available
    
    

    
    Int J Hematol

18. ILORI EO, Kandathil A, Chen W
    Unusual presentation of hairy cell leukemia as a retroperitoneal nodal mass: a diagnostic pitfall.
    Int J Hematol. 2026 Aug 31. doi: 10.1007/s12185-026-04274.
    PubMed        
    
    
19. NAKATA Y, Hiratsuka A, Yoroidaka T, Takahashi W, et al
    Late acquisition of BCR::ABL1 during clonal evolution of SAMD9-associated MDS with phenotypic shift from AML to B-ALL.
    Int J Hematol. 2026;124:443-446.
    PubMed         Abstract available
    
    
20. KOIZUMI R, Takagi S, Nishida A, Kuno M, et al
    Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study.
    Int J Hematol. 2026;124:328-333.
    PubMed         Abstract available
    
    
21. SHIMOSATO Y, Goyama S
    NPM1-rearranged AML: clinical features, molecular pathogenesis, and therapeutic perspectives.
    Int J Hematol. 2026;124:303-310.
    PubMed         Abstract available
    
    
22. IDA N, Okura M, Tanaka S, Hosono N, et al
    Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines.
    Int J Hematol. 2026;124:348-360.
    PubMed         Abstract available
    
    

    
    Leukemia

23. TALLEUR AC, Metais JY, Li Y, Schell S, et al
    CD19-CAR T cells persist long-term in the cerebrospinal fluid of pediatric, adolescent and young adult patients with B-cell acute lymphoblastic leukemia.
    Leukemia. 2026 Sep 3. doi: 10.1038/s41375-026-03108.
    PubMed        
    
    
24. YANG M, Lu T, He Y, Chen C, et al
    KLF4/MLL3 complex axis drives NRBP2 transcription to eliminate acute myeloid leukemia cells.
    Leukemia. 2026 Sep 2. doi: 10.1038/s41375-026-03117.
    PubMed         Abstract available
    
    
25. YATES SJ, Terman E, Miller L, Cursio JF, et al
    Association of sarcopenia with treatment tolerance in older adults with acute myeloid leukemia using artificial intelligence computed tomography-segmentation and a geriatric assessment.
    Leukemia. 2026 Aug 31. doi: 10.1038/s41375-026-03099.
    PubMed        
    
    
26. BADAR T, Foran J, Jamy O, Lin C, et al
    Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.
    Leukemia. 2026 Aug 31. doi: 10.1038/s41375-026-03119.
    PubMed         Abstract available
    
    
27. MOSER LM, Hutter M, Ahlmann M, Alonso-Saladrigues A, et al
    Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome.
    Leukemia. 2026 Aug 31. doi: 10.1038/s41375-026-03105.
    PubMed         Abstract available
    
    

    
    N Engl J Med

28. FATHI AT, Perl AE, Fell GG, Jonas BA, et al
    Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.
    N Engl J Med. 2026;395:845-858.
    PubMed         Abstract available
    
    

    
    PLoS One

29. BOSU P, Adhikary T, Rafi AS, Iqbal N, et al
    Acute Myeloid Leukemia(AML) proteins for in silico drug design using pharmacophore modeling, molecular docking and molecular dynamics simulation.
    PLoS One. 2026;21:e0354456.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

30. LI S, He S, Su Y, Wang L, et al
    AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness.
    Proc Natl Acad Sci U S A. 2026;123:e2608310123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum